Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Learn How Coronary IVL is Currently Utilized Within Non-Surgical Facilities
Want to learn more about Coronary IVL’s place within existing facilities lacking surgical cardiac backup? Cardiovascular Business and Shockwave Medical is excited to present this on demand webinar titled: No Surgical Backup? No Problem. This webinar consists of an expert panel who provide real-world insights and implications of Coronary IVL usage within non-surgical facilities. Topics within this event include a review of the recent SCAI Expert Consensus Document regarding PCI within non-surgical facilities, an introduction to Shockwave IVL, and a real-world clinical and administrational perspective of Coronary IVL within an existing non-surgical facility. A fantastic roundtable discussion and Q+A close the webinar with additional insights regarding Coronary IVL within these important facilities.
The webinar and additional information regarding Coronary IVL and non-surgical facilities can be found at the links below.
Topics: Coronary IVL, Shockwave C2
2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Updated SCAI guidance includes Coronary IVL as a treatment option in all U.S. cath labs regardless of surgical backup status.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Dear Interventional Community,
Topics: SWAV News
CMS Corrects Error for IVL Procedures in ASC Setting – Retroactive TPT Payment Eligible for 2022
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Für eine deutschsprachige Version klicken Sie HIER
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Verbesserte Kostenerstattung für koronare IVL in Deutschland
For an English language version, click HERE
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Dr. Misty Humphries reviews the sex specific analysis from the Disrupt PAD III Observational Study while at VIVA 2022. Because females often present with more difficult characteristics for endovascular therapy, this analysisof 1,373 patients aimed to illustrate that IVL can safely and effectively modify calcium regardless of gender. Dr. Humphries shares that despite women having smaller vessels, the complication rate was extremely low, with no significant difference in embolization or perforations when using Shockwave IVL to treat PAD.
Check out the presentation below and hear from Dr. Humphries on the importance of this ‘real-world’ data set in the treatment of heavily calcified PAD.
Topics: Peripheral IVL
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
